<DOC>
	<DOC>NCT01514344</DOC>
	<brief_summary>Phase II, monocentric, open label study to assess safety and activity of intralesional Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.</brief_summary>
	<brief_title>Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma</brief_title>
	<detailed_description>Preliminary data suggest intralesional rituximab is able to revert resistance to systemic rituximab in patients with CD20+ indolent lymphoma of the conjunctiva, and the addition of autologous serum seems to exhibit a synergistic effect on tumor regression. These two main aspects will be assessed in this trial.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>histological diagnosis of CD20+ B cell lymphoma subtypes: marginal zone lymphoma, grade 12 follicular lymphoma, plasmocytic lymphoma, small lymphocyte lymphoma conjunctival localization alone (1EA stage; mono or bilateral) at least one measurable lesion age &gt;/= 18 years ECOGPS &lt;/=3 HIV 12 negativity at least one previous treatment (antibiotic or rituximab) concomitant conventional (chemo, radiation, immuno), experimental (antibiotic) or corticosteroid anticancer therapy known allergy to rituximab systemic symptoms concurrent diagnosis of pemphigus postsurgical conjunctival scars</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>OAL</keyword>
	<keyword>MALT</keyword>
	<keyword>conjunctiva</keyword>
	<keyword>indolent</keyword>
	<keyword>CD20+</keyword>
</DOC>